Articles On Dimerix (ASX:DXB)

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Dimerix receives upfront payment of ¥300 million (~A$3.2 million) from FUSO Pharmaceutical Industries under licensing deal Company recently inked licensing deal with Japanese company for phase III asset in kidney disease DMX-200 Dimerix el...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January. Under that deal, FUSO and Dimerix teamed up to develop and commercialise D...

Polynovo and Avita Medical are victims of skittish market behaviour Cyclopharm breathes easier after a good start with US sales Control Bionics raises $2 million to rev up commercialisation   Investor reaction to PolyNovo’s (ASX:PNV) half...

Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy (BIS) device for early detection and prevention of lymph...

Highlights Rapid sector growth offers new prospects for ASX-listed healthcare firms Key players (IPD,DXB,IMR) are enhancing regional presence Rising demand driven by innovation and demographic trends fuels market expansion The healthc...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 closed up 1.38% at 8,327 points. Unemployment ticked up to 4%, in line with consensus expectations. The strong jobs data has increased the threshold on what the RBA will need to see in the December quarter inflation numbers fo...

ASX jumps on strong banks and jobs report Zip and Tabcorp surge as markets rally Oil prices soar amid supply risks and cold weather   The ASX flexed its muscles today, up 1.38% on the back of strong bank gains and a bit of global risk-on...

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research. The trial will investigate the...

Pro Medicus signs $33m deal with University of Kentucky Memphasys’ RoXsta system advances antioxidant profiling potential Acrux launches 90-gram Dapsone Gel in US   These are today’s healthcare announcements from the ASX, with major progr...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, inc...

Highlights Dimerix (ASX:DXB) successfully enrolls its first pediatric patient in the ACTION3 trial targeting FSGS. The ACTION3 trial spans 19 sites across multiple countries, with a focus on pediatric patients aged 12 to 17. Successfu...

This week’s Bulls N’ Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight, while Argent Biopharma, Australian Mines and Dimerix also ran hard.

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

Opyl enters joint venture with X Firm to market its AI-powered TrialKey platform in Europe, Middle East, Africa and North America Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-20...

The ASX200 has been up one fifth of a percent (0.2%) at 8,273 points in afternoon trade. Canada’s Prime Minister Justin Trudeau has resigned and the country’s main stock index fell on Monday; the Loonie notched a near three-week high. Bo...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara tells all on Dimerix’s (ASX:DXB) new partner in Japan’s FUSO Pharmaceutical Industries to develop a drug candidate in fig...

Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 in Japan to treat FSGS Fuso responsible for development costs, obtaining regulatory approval, sales and marketing in Japan Deal...

Biopharmaceutical company Dimerix Ltd (ASX:DXB) has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease....

Dimerix Ltd (ASX: DXB) shares are catching the eye of investors on Tuesday. In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Why is this ASX healthcare stock rocketing? Investors have been fighting to get hold of the clin...

The ASX 200 index is expected to open as much as 0.36% higher today, adding 29.9 points in futures, which would mark the local bourse’s fourth green day in a row – a trend it just barely held on to yesterday at close. U.S. markets were c...

The second last day of the year on the Australian stock exchange looks red, with the shortened holiday trading week’s futures down just over 29 points – a 0.35% drop – as the Aussie bourse grinds to a sluggish end to the 2025 season. The...

Highlights Market Performance: The ASX dipped 0.35% in early trading as global market pressures and profit-taking weighed on sentiment. Sector Impacts: Key players in tech and retail, including Microsoft and Amazon, showed declines,...

Highlights - ASX faced a modest dip amid global caution and ex-dividend activity.  - BrainChip Holdings (BRN) soared despite no clear catalyst for its rise.  - Prominent small-cap stocks showcased diverse developments and partnerships....

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX dips as energy stocks lead losses Global tensions weigh on markets, gold stocks rise China holds rates steady, Nvidia’s earnings later tonight   The ASX slipped from Tuesday’s high, closing lower by 0.57% on Wednesday.  Global worries...

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

Stocks surge and US dollar jumps as Trump leads ASX rises  amid tight US election race Bitcoin hits record as Trump-linked trades soar   Stocks surged, Treasury yields soared, and the US dollar looked set for its biggest gain since March...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership   The ASX kicked off November with a thud, sliding about 0.5%. This  follows a tough session o...

ASX set to open lower after Wall Street tech stocks slump Amazon soars on strong holiday sales forecast Roblox and Peloton shares surge while Robinhood drops   The ASX is set to fall when the market resumes on Friday after a very rough da...

PARASOL working group confirms eGFR as an approved surrogate endpoint for FDA approval of treatments for focal segmental glomerulosclerosis The working group also determined that proteinuria alone may also be suitable for FDA full approva...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

  ASX hits all-time high before retreating slightly Gold miners surge as prices near record high Hong Kong falls on weak China data; Yen rises     The ASX briefly hit an all-time high on Monday before paring gains. At the close of the da...

The Pilbara Minerals Ltd (ASX: PLS) share price has soared an incredible 20% over the last week, recovering the ground that it lost during the first 10 days of September, as shown on the chart below. It may not come as a complete surp...

The ASX200 has closed up 1.1% at 8,075 points. The Aussie bourse followed Wall Street’s tech sector higher, despite US investors reducing expectations of an up-sized Fed rate cute next week. Back home, all sectors gained ground and the I...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a convincing return to form this Thursday, rising enthusiastically after several days of stagnation. The ASX 200 clos...

  ASX climbs with tech, energy, and uranium stocks driving gains Uranium stocks surge as Putin hints at possible export limits Lithium miners rise on growing demand, while WiseTech hits a new record high   The ASX took a leap on Thursday...